BDBM103350 US8552202, Compound 2

SMILES F[C@H]1CN([C@H]2[C@@H]1OCC2=O)C(=O)[C@@H](NC(=O)c1ccccc1)C1CCCCC1

InChI Key InChIKey=KKKHMKQUVHHTJX-GDAAHCPNSA-N

Data  5 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 103350   

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103350(US8552202, Compound 2)
Affinity DataKi:  59nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103350(US8552202, Compound 2)
Affinity DataKi:  95nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetProcathepsin L(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103350(US8552202, Compound 2)
Affinity DataKi:  580nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin L2(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103350(US8552202, Compound 2)
Affinity DataKi:  700nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin B(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103350(US8552202, Compound 2)
Affinity DataKi: >7.00E+3nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent